ahlam1399
07-11-2016, 11:40 AM
BRIEF-Diurnal Group says primary endpoint met in Infacort late-stage study
* Positive headline data from pivotal study for Infacort in Europe for paediatric adrenalinsufficiency (AI)http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=zwQyEiRGnDo:Fea2UBR41f8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zwQyEiRGnDo:Fea2UBR41f8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=zwQyEiRGnDo:Fea2UBR41f8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zwQyEiRGnDo:Fea2UBR41f8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=zwQyEiRGnDo:Fea2UBR41f8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/zwQyEiRGnDo
* Positive headline data from pivotal study for Infacort in Europe for paediatric adrenalinsufficiency (AI)http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=zwQyEiRGnDo:Fea2UBR41f8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zwQyEiRGnDo:Fea2UBR41f8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=zwQyEiRGnDo:Fea2UBR41f8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zwQyEiRGnDo:Fea2UBR41f8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=zwQyEiRGnDo:Fea2UBR41f8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/zwQyEiRGnDo